ホーム › 乳がん › ノースカロライナ › Charlotte
Charlotte、NCにおける乳がんの臨床試験
Charlotteとその周辺地域（約30マイル以内）の拠点で、乳がんに関する22件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
被験者募集中第2相
- Levine Cancer, Charlotte
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
被験者募集中第1相
- Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center, Huntersville · 13マイル先
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
被験者募集中第3相
- Novant Health Cancer Institute ( Site 0019), Charlotte
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
被験者募集中第3相
- Levine Cancer Institute ( Site 0014), Charlotte
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
被験者募集中第3相
- Levine Cancer Institute, Charlotte
- Levine Cancer Institute, Charlotte
- Levine Cancer Institute, Charlotte
- 他7件
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
被験者募集中
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
被験者募集中
- Atrium Levine Cancer Institute, Charlotte
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
被験者募集中第3相
- Clinical Trial Site, Charlotte
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
被験者募集中第3相
- Atrium Health, Charlotte
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
被験者募集中第3相
- Oncology Specialists of Charlotte Pa, Charlotte
- Carolina Oncology Specialists, Charlotte
Utility of a Mobile Application for Young Women With Breast Cancer
被験者募集中
- Atrium Health Levine Cancer, Charlotte
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
被験者募集中第1/2相
- Research Site, Charlotte
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
被験者募集中第1/2相
- Levine Cancer Institute, Charlotte
- Novant Health Cancer Institute, Charlotte
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
被験者募集中第3相
- Novant Health Cancer Institute, Charlotte
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
被験者募集中第3相
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Novant Health Presbyterian Medical Center, Charlotte
- Atrium Health Pineville/LCI-Pineville, Charlotte
- 他12件
E-Mindfulness Approaches for Living After Breast Cancer
被験者募集中第3相
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Atrium Health Pineville/LCI-Pineville, Charlotte
- Levine Cancer Institute-SouthPark, Charlotte
- 他7件
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
被験者募集中第2相
- GSK Investigational Site, Charlotte
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Carolina BioOncology Institute, Huntersville · 13マイル先
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
被験者募集中第3相
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Novant Health Presbyterian Medical Center, Charlotte
- Atrium Health Pineville/LCI-Pineville, Charlotte
- 他10件
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
被験者募集中第1/2相
- Levine Cancer Institute (LCI)- Atrium Health, Charlotte
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
被験者募集中観察研究
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Atrium Health Pineville/LCI-Pineville, Charlotte
- Levine Cancer Institute-SouthPark, Charlotte
- 他8件
EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
被験者募集中観察研究
- Atrium Health Levine Cancer Institute, Charlotte
- Novant Health Cancer Institute - Elizabeth, Charlotte
他の都市における乳がんの試験
- New York City, NY136件の研究
- Houston, TX126件の研究
- Boston, MA112件の研究
- Nashville, TN81件の研究
- Los Angeles, CA73件の研究
- Edison, NJ68件の研究
- St. Louis, MO64件の研究
- Queens, NY64件の研究
- Durham, NC64件の研究
- Chicago, IL59件の研究
- Philadelphia, PA56件の研究
- Dallas, TX55件の研究
Charlotteにおける他の研究
- がん（全種類）27件の研究
- 多発性骨髄腫21件の研究
- 非小細胞肺癌19件の研究
- 急性骨髄性白血病16件の研究
- 肥満症16件の研究
- 過体重15件の研究
- 大腸癌13件の研究
- 卵巣がん12件の研究
- 心不全11件の研究
- 転移性癌11件の研究
- 頭頸部扁平上皮癌10件の研究
- COPD9件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。